The Itch That Won’t Quit: Incyte’s New Hope for Prurigo Nodularis
The 2025 American Academy of Dermatology Annual Meeting featured Incyte Corporation’s pivotal Phase 3 TRuE-PN clinical trials for prurigo nodularis, showcasing promising results. Incyte’s ruxolitinib cream, marketed as Opzelura, demonstrated significant efficacy, with nearly 45% of patients reporting a reduction in itch
